Announcement on Change of the Accounting Officer

USPTO Approved the Patent Application for OBI-888 “Antibodies, pharmaceutical compositions and uses thereof”
October 6, 2017
OBI Plans to Issue New Shares in Exchange for the AP Biosciences, Inc. Shares Owned by AbProtix,Inc, Subject to Regulatory Approval
October 20, 2017
  1. Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel(CEO, COO, CMO, CSO, etc.),financial officer, accounting officer, research and development officer, or internal audit officer): Accounting Officer
  2. Date of occurrence of the change: October 20, 2017
  3. Name, title, and resume of the replaced person: Max Chan, Chief Operating Officer
  4. Name, title, and resume of the replacement: Colin Kao, Certified Public Accountant (U.K. and Taiwan), Manager, Finance.
  5. Type of the change (please enter: “resignation”, “position adjustment”, “dismissal”, “retirement”, “death” or “” ): Position adjustment
  6. Reason for the change: Position adjustment
  7. Effective date: October 20, 2017
  8. Contact telephone number of the replacement: (02)2786-6589
  9. Any other matters that need to be specified: Max Chan remains as the Financial Officer of the company